Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
暂无分享,去创建一个
M. Sormani | A. Uccelli | G. Mancardi | C. Solaro | A. Laroni | E. Capello | M. Pizzorno | T. Tassinari | S. Parodi | I. Gandoglia | S. Venturi | G. Ribizzi | Giovanna Baldassarre | M. T. Rilla
[1] J. Sargento-Freitas,et al. Clinical predictors of an optimal response to natalizumab in multiple sclerosis , 2013, Journal of Clinical Neuroscience.
[2] C. Pozzilli,et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis , 2012, Journal of the Neurological Sciences.
[3] L. Grimaldi,et al. Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification , 2012, Journal of Neuroimmune Pharmacology.
[4] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[5] H. Norton,et al. Course of relapsing–remitting multiple sclerosis before, during and after natalizumab , 2011, Multiple sclerosis.
[6] J. L. Poveda-Andrés,et al. Evaluación de la efectividad y la seguridad del natalizumab en el tratamiento de la esclerosis múltiple remitente recidivante , 2011 .
[7] G. Moonen,et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.
[8] E. de Ramón,et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study , 2011, Multiple sclerosis.
[9] G. Fenu,et al. The cohort of the multiple sclerosis center of Cagliari , 2011, Neurological Sciences.
[10] T. Olsson,et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis , 2011, Multiple sclerosis.
[11] Michael Hutchinson,et al. New perspectives in the natural history of multiple sclerosis , 2010, Neurology.
[12] M. Calabrese,et al. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[13] N. Putzki,et al. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries , 2010, European journal of neurology.
[14] G. Comi,et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience , 2009, Neurological Sciences.
[15] N. Putzki,et al. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis , 2009, European journal of neurology.
[16] G. Tedeschi,et al. Natalizumab: a country-based surveillance program , 2008, Neurological Sciences.
[17] G. Antonelli,et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.
[18] S. Martínez-Yélamos,et al. Regression to the mean in multiple sclerosis , 2006, Multiple sclerosis.
[19] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[20] B. Casanova,et al. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. , 2011, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
[21] C. Pozzilli,et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome , 2010, Neurological Sciences.
[22] G. Comi,et al. Three years of experience: the Italian registry and safety data update , 2010, Neurological Sciences.
[23] G. Comi,et al. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study , 2010, Neurological Sciences.